^
    2years
    Evaluation of GLR2007 for Advanced Solid Tumors (clinicaltrials.gov)
    P1b/2, N=19, Completed, Gan and Lee Pharmaceuticals, USA | Active, not recruiting --> Completed | N=66 --> 19
    Trial completion • Enrollment change • Metastases
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    GLR2007
    3years
    Evaluation of GLR2007 for Advanced Solid Tumors (clinicaltrials.gov)
    P1b/2, N=66, Active, not recruiting, Gan and Lee Pharmaceuticals, USA | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    GLR2007
    over4years
    Evaluation of GLR2007 for Advanced Solid Tumors (clinicaltrials.gov)
    P1b/2, N=66, Recruiting, Gan and Lee Pharmaceuticals, USA | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    GLR2007